Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

NCT06539208 is registered in ClinicalTrials.gov with YolTech Therapeutics Co., Ltd as lead sponsor.

NCT NCT06539208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06539208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Lead sponsor
YolTech Therapeutics Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 23, 2024
Completion date
June 30, 2026
Enrollment
31 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

transthyretin amyloidosis polyneuropathy, transthyrexin amyloidosis cardiomyopathy